1. The Medicines Transparency Alliance Saul Walker Senior Policy Advisor, Access to Medicines Health Services Team

2. Page 2 Pharmaceutical markets Public and private International and local interactions Information asymmetry Manufacturer/(regulator)/purchaser Wholesaler/Retailer Prescriber/(Dispenser)/Patient Lack of information Irrational – unaligned incentives

3. Page 3 The hypothesis … Transparency Mutual Accountability Efficiency (public/private) Multi-stakeholder disclosure & scrutiny Better policies, improved business practice & stronger implementation Validated Information & Appropriate Disclosure

4. 7 countries committed to work across government, private sector and civil society to disclose data on medicines price, quality, availability and promotion Medicines Transparency Alliance

5. Page 5 Country Priorities Commit to disclosure and multi- stakeholder approach Must include CSOs and private sector Decide where to locate secretariat and stakeholder group Agree priority areas and work plan Guidance on disclosure from International Secretariat Methodologies and technical support

6. Page 6 The Pilot New validated data on pharmaceutical sector Disclosure of data and scrutiny by multi- stakeholder group Development of policy options Policy change and implementation Changes in drug prices, availability, quality and/or promotion Improved information for management Improved processes. New validated data on pharmaceutical sector New validated data on pharmaceutical sector Disclosure of data and scrutiny by multi- stakeholder group Development of policy options Policy change and implementation Changes in drug prices, availability, quality and/or promotion Changes in drug prices, availability, quality and/or promotion Improved information for management Improved processes. Pilot ££, toolkit & technical support Policy research, shared learning Sector plans, domestic and CPs

7. Page 7 Priorities chosen by countries

8. Page 8 Data disclosure (in addition to baseline) Pricing (Peru and Uganda) Availability and promotion (Jordan and Zambia); Transparency and accountability (Philippines - GGM) Quality (Kyrgyzstan and Ghana); Health insurance data mining (Ghana) RUM (Uganda and Jordan)

9. Page 9 Progress and Next Steps All countries have agreed work plans – took longer than we expected Implementation now underway – focus on newly disclosing & using information Baseline surveys underway Sector scan, availability, multi-stakeholder working – significant new data resources Process evaluation 1Q10 – inform decisions and design for post-pilot

10. Page 10 Questions Disclosure – what, when and to whom? Multi-stakeholder approach or multi- stakeholder analysis? Catalysing support from others? Adding value or adding confusion?

11. Page 11 www.medicinestransparency.org